Fibrinogen and cardiovascular disease: Genetics and biomarkers

Blood Reviews

Volumn 25, Issue 6, 2011, Pages 239-245

  Tousoulis, Dimitris ^a   Papageorgiou, Nikolaos ^a   Androulakis, Emmanuel ^a   Briasoulis, Alexandros ^a   Antoniades, Charalambos ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Coagulation; Coronary artery disease; Fibrinogen; Genetic polymorphisms; Inflammatory biomarkers

Indexed keywords

BIOLOGICAL MARKER; FIBRINOGEN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL OBSERVATION; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DNA POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

ANIMALS; CORONARY DISEASE; FIBRINOGEN; HUMANS; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC;

EID: 80055001710     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2011.05.001     Document Type: Article

References (61)

1. Papageorgiou N., Tousoulis D., Siasos G., Stefanadis C. Is fibrinogen a marker of inflammation in coronary artery disease?. Hellenic J Cardiol 2010, 51:1-9.
2. Maresca G., Di Blasio A., Marchioli R., Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol 1999, 19:1368-1377.
3. Stefanadi E., Tousoulis D., Papageorgiou N., Briasoulis A., Stefanadis C. Inflammatory biomarkers predicting events in atherosclerosis. Curr Med Chem 2010, 17:1690-1707.
4. Carcaillon L., Gaussem P., Ducimetière P., et al. Elevated plasma fibrin D-dimer as a risk factor for vascular dementia: the Three-City cohort study. J Thromb Haemost 2009, 7:1972-1978.
5. Maison P., Mennen L., Sapinho D., et al. A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration. Atherosclerosis 2002, 160:155-160.
6. Kaptoge S., White I.R., Thompson S.G., et al. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the Fibrinogen Studies Collaboration. Am J Epidemiol 2007, 166:867-879.
7. Vischetti M., Zito F., Donati M.B., Iacoviello L. Analysis of gene-environment interaction in coronary heart disease: fibrinogen polymorphisms as an example. Ital Heart J 2002, 3:18-23.
8. Herrick S., Blanc-Brude O., Gray A., Laurent G. Fibrinogen. Int J Biochem Cell Biol 1999, 31:741-746.
9. Forsyth C.B., Solovjov D.A., Ugarova T.P., Plow E.F. Integrin alpha (M)beta (2)-mediated cell migration to fibrinogen and its recognition peptides. J Exp Med 2001, 193:1123-1133.
10. Schneider D.J., Taatjes D.J., Howard D.B., Sobel B.E. Increased reactivity of platelets induced by fibrinogen independent of its binding to the IIb-IIIa surface glycoprotein: a potential contributor to cardiovascular risk. J Am Coll Cardiol 2001, 33:261-266.
11. Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101:1767-1772.
12. Meade T.W., Mellows S., Brozovic M., et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986, 2:533-537.
13. Assmann G., Cullen P., Heinrich J., Schulte H. Hemostatic variables in the prediction of coronary risk: results of the 8year follow-up of healthy men in the Munster Heart Study (PROCAM). Prospective Cardiovascular Munster Study. Isr J Med Sci 1996, 32:364-370.
14. Juhan-Vague I., Thompson S.G., Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. Arterioscler Thromb 1993, 13:1865-1873.
15. Wattanakit K., Folsom A.R., Chambless L.E., Nieto F.J. Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2005, 149:606-612.
16. Handa K., Kono S., Saku K., et al. Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis. Atherosclerosis 1989, 77:209-213.
17. Umemoto S., Suzuki N., Fujii K., et al. Eosinophil counts and plasma fibrinogen in patients with vasospastic angina pectoris. Am J Cardiol 2000, 85:715-719.
18. Held C., Hjemdahl P., Håkan Wallén N., et al. Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable angina pectoris. Results from the APSIS study. The Angina Prognosis Study in Stockholm. Atherosclerosis 2000, 148:179-188.
19. van der Bom J.G., de Maat M.P., Bots M.L., et al. Elevated plasma fibrinogen: cause or consequence of cardiovascular disease?. Arterioscler Thromb Vasc Biol 1998, 18:621-625.
20. Martin J.F., Bath P.M., Burr M.L. Mean platelet volume and myocardial infarction. Lancet 1992, 338:1409-1411.
21. Scarabin P.Y., Aillaud M.F., Amouyel P., et al. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction-the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Thromb Haemost 1998, 80:749-756.
22. Dalmon J., Laurent M., Courtois G. The human beta fibrinogen promoter contains a hepatocyte nuclear factor 1-dependent IL-6-responsive element. Mol Cell Biol 1993, 13:1183-1193.
23. Lane D.A., Grant P.J. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000, 95:1517-1532.
24. Smith G.D., Harbord R., Milton J., Ebrahim S., Sterne J.A. Does elevated plasma fibrinogen increase the risk of coronary heart disease? Evidence from a meta-analysis of genetic association studies. Arterioscler Thromb Vasc Biol 2005, 25:2228-2233.
25. Keavney B., Danesh J., Parish S., et al. Fibrinogen and coronary heart disease: test of causality by "Mendelian randomisation". Int J Epidemiol 2006, 35:935-943.
26. Kolz M., Baumert J., Gohlke H., et al. Association study between variants in the fibrinogen gene cluster, fibrinogen levels and hypertension: results from the MONICA/KORA study. Thromb Haemost 2009, 101:317-324.
27. Carty C.L., Cushman M., Jones D., et al. Associations between common fibrinogen gene polymorphisms and cardiovascular disease in older adults. The Cardiovascular Health Study. Thromb Haemost 2008, 99:388-395.
28. Albert M.A., Pare G., Morris A., et al. Candidate genetic variants in the fibrinogen, methylenetetrahydrofolate reductase, and intercellular adhesion molecule-1 genes and plasma levels of fibrinogen, homocysteine, and intercellular adhesion molecule-1 among various race/ethnic groups: data from the Women's Genome Health Study. Am Heart J 2009, 157:777-783.
29. Jood K., Danielson J., Ladenvall C., Blomstrand C., Jern C. Fibrinogen gene variation and ischemic stroke. J Thromb Haemost 2008, 6:897-904.
30. Siegerink B., Rosendaal F.R., Algra A. Genetic variation in fibrinogen; its relationship to fibrinogen levels and the risk of myocardial infarction and ischemic stroke. J Thromb Haemost 2009, 7:385-390.
31. Jacquemin B., Antoniades C., Nyberg F., et al. Common genetic polymorphisms and haplotypes of fibrinogen alpha, beta, and gamma chains affect fibrinogen levels and the response to proinflammatory stimulation in myocardial infarction survivors: the AIRGENE study. J Am Coll Cardiol 2009, 52:941-952.
32. Dehghan A., Yang Q., Peters A., et al. Association of novel genetic loci with circulating fibrinogen levels: a genome-wide association study in 6 population-based cohorts. Circ Cardiovasc Genet 2009, 2:125-133.
33. Mannila M.N., Eriksson P., Lundman P., et al. Contribution of haplotypes across the fibrinogen gene cluster to variation in risk of myocardial infarction. Thromb Haemost 2005, 93:570-577.
34. Kathiresan S., Yang Q., Larson M.G., et al. Common genetic variation in five thrombosis genes and relations to plasma hemostatic protein level and cardiovascular disease risk. Arterioscler Thromb Vasc Biol 2006, 26:1405-1412.
35. Green F.R. Fibrinogen polymorphisms and atherothrombotic disease. Ann N Y Acad Sci 2001, 936:549-559.
36. Zee R.Y., Cook N.R., Cheng S., Erlich H.A., Lindpaintner K., Ridker P.M. Multi-locus candidate gene polymorphisms and risk of myocardial infarction: a population-based, prospective genetic analysis. J Thromb Haemost 2006, 4:341-348.
37. Koch W., Hoppmann P., Biele J., Mueller J.C., Schömig A., Kastrati A. Fibrinogen genes and myocardial infarction: a haplotype analysis. Arterioscler Thromb Vasc Biol 2008, 28:758-763.
38. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 2003, 89:601-609.
39. Kallner A., Egberg N., Yu A., et al. Are results of fibrinogen measurements transferable?. Clin Chem Lab Med 2003, 41:804-808.
40. van den Besselaar A.M., Haas F.J., van der Graaf F., Kuypers A.W. Harmonization of fibrinogen assay results: study within the framework of the Dutch project 'Calibration 2000'. Int J Lab Hematol 2009, 31:513-520.
41. Rana J.S., Cote M., Després J.P., et al. Inflammatory biomarkers and the prediction of coronary events among people of intermediate risk: the EPIC-Norfolk prospective population study. Heart 2009, 90:1682-1687.
42. Chuang S.Y., Bai C.H., Chen W.H., Lien L.M., Pan W.H. Fibrinogen independently predicts the development of ischemic stroke in a Taiwanese population: CVDFACTS study. Stroke 2009, 40:1578-1584.
43. del Zoppo G.J., Levy D.E., Wasiewski W.W., et al. Hyperfibrinogenemia and functional outcome from acute ischemic stroke. Stroke 2009, 40:1687-1691.
44. Rizzo M., Corrado E., Coppola G., Muratori I., Novo G., Novo S. Markers of inflammation are strong predictors of subclinical and clinical atherosclerosis in women with hypertension. Coron Artery Dis 2009, 20:15-20.
45. Green D., Chan C., Kang J., et al. Longitudinal assessment of fibrinogen in relation to subclinical cardiovascular disease: the CARDIA study. J Thromb Haemost 2010, 8:489-495.
46. Tzoulaki I., Murray G.D., Lee A.J., Rumley A., Lowe G.D., Fowkes F.G. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke. The Edinburgh Artery Study. Circulation 2007, 115:2119-2127.
47. Sjöland H., Tengborn L., Stensdotter L., Herlitz J. Lack of very strong association between pre-treatment fibrinogen and PAI-1 with long-term mortality after coronary bypass surgery. Cardiology 2007, 108:82-89.
48. Lawlor D.A., Smith G.D., Rumley A., Lowe G.D., Ebrahim S. Associations of fibrinogen and C-reactive protein with prevalent and incident coronary heart disease are attenuated by adjustment for confounding factors. British Women's Heart and Health Study. Thromb Haemost 2005, 93:955-963.
49. Smith A., Patterson C., Yarnell J., Rumley A., Ben-Shlomo Y., Lowe G. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 2005, 112:3080-3087.
50. Danesh J., Lewington S., Thompson S.G., et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005, 294:1799-1809.
51. Pineda J., Marín F., Marco P., Roldán V., et al. Premature coronary artery disease in young (age <45) subjects: interactions of lipid profile, thrombophilic and haemostatic markers. Int J Cardiol 2009, 136:222-225.
52. Tousoulis D., Davies G., Tentolouris C., Bosinakou E., Toutouzas P. Relation of von Willebrand factor to occurrence of Q waves and thrombolytic treatment in acute myocardial infarction. Am J Cardiol 1998, 81:497-500.
53. Folsom A.R., Wu K.K., Rosamond W.D., Sharrett A.R., Chambless L.E. Prospective study of hemostatic factors and incidence of coronary heart disease. Circulation 1997, 96:1102-1108.
54. Robinson D.M., Schwahn C., Alte D., John U., Felix S.B., Völzke H. Plasma fibrinogen levels are associated with a strong family history of myocardial infarction. Blood Coagul Fibrinolysis 2004, 15:497-502.
55. Espinola-Klein C., Rupprecht H.J., Bickel C., et al. Inflammation, atherosclerotic burden and cardiovascular prognosis. Atherosclerosis 2007, 195:126-134.
56. Papageorgiou N., Tousoulis D., Miliou A., et al. The role of the G455A polymorphism on fibrinogen b-chain gene in advanced atherosclerosis: effects on fibrinogen, D-dimers and plasminogen levels. Eur Heart J Suppl 2010, 31(Suppl. I):484.
57. Tousoulis D., Koumallos N., Antoniades C., et al. Genetic polymorphism on type 2 receptor of angiotensin II, modifies cardiovascular risk and systemic inflammation in hypertensive males. Am J Hypertens 2010, 23:237-242.
58. Sun A.J., Ma H.L., Chen X.Y., et al. Association of fibrinogen and fibrinogen gene beta148 and beta854 polymorphisms with coronary heart disease. Cardiology 2008, 111:167-170.
59. Mannila M.N., Lovely R.S., Kazmierczak S.C., et al. Elevated plasma fibrinogen gamma' concentration is associated with myocardial infarction: effects of variation in fibrinogen genes and environmental factors. J Thromb Haemost 2007, 5:766-773.
60. Boekholdt S.M., Sandhu M.S., Wareham N.J., Luben R., Reitsma P.H., Khaw K.T. Fibrinogen plasma levels modify the association between the factor XIII Val34Leu variant and risk of coronary artery disease: the EPIC-Norfolk prospective population study. J Thromb Haemost 2006, 4:2204-2209.
61. van't Hooft F.M., von Bahr S.J., Silveira A., Iliadou A., Eriksson P., Hamsten A. Two common, functional polymorphisms in the promoter region of the beta-fibrinogen gene contribute to regulation of plasma fibrinogen concentration. Arterioscler Thromb Vasc Biol 1999, 19:3063-3070.